期刊文献+

9-硝基喜树碱犬体内药代动力学研究 被引量:4

Pharmacokinetics of 9-nitro-camptothecin in Beagle dogs
下载PDF
导出
摘要 目的:研究9硝基喜树碱在犬体内药动学规律。方法:犬静注或灌服3个剂量9硝基喜树碱,血浆9硝基喜树碱浓度用高效液相色谱法及液相质谱联用法检测,浓度时间数据用3P97药代动力学软件进行分析,计算药动学参数,分析AUC、Cmax及ke与剂量的线性关系。结果:犬静注0.5、1、2mg·kg-19硝基喜树碱,t12分别为2.2±2.2、1.8±1.7和0.8±0.6h;AUC0-t分别为105±71、272±81和396±93ng·h·ml-1;犬灌胃1、2、4mg·kg-19硝基喜树碱,Cmax分别为9.3±8.2、42.2±35.7和63.6±5.9ng·ml-1,Tmax分别为0.3±0.1、0.2±0.1、0.4±0.1h,t12分别为1.9±1.3、1.0±0.6和2.8±1.5h,AUC0-t分别为8.9±7.2、16.3±12.3和59.5±25.5ng·h·ml-1;各剂量组t12及ke与剂量无关(P>0.05);口服生物利用度<6%。结论:静脉及灌胃给药后,9硝基喜树碱在犬体内的动力学过程符合二室模型,在本实验所用的剂量范围内为线性动力学过程。9硝基喜树碱灌胃给药后吸收迅速,口服生物利用度低。 AIM: To study the pharmacokinetics of 9-nitro-camptothecin ( 9-NC ) in dogs. METHODS:Each Beagle dog was given a single dose of 9-NC by iv or ig administration. The concentrations of 9-NC in plasma were detected by HPIE and HPLC-MS. Pharmacokinetic parameters were determined from the plasma concentration-time data with the 3P97 software package. The relationships between AUC, Cmax or ke and dose were evaluated by linear regression. RESULTS: After iv administration of 9-NC at the dose of 0.5, 1, and 2 mg·kg%-1, the t1/2 values of 9-NC were 2.2 ± 2.2, 1.8 ± 1.7 and 0.8 ± 0.6 h, respectively, and AUC0-1, were 105 ± 71, 272 ± 81 and 396 ±93 ng·h·ml^-1 , respectively. After ig administration of 9-NC at the dose of l, 2, and 4 mg·kg^-1, 9-NC was rapidly absorbed, reaching Cmax of 9.3 ± 8.2, 42±36 and 64±6 ng·ml^-1 at Tmax, of 0.3±0.1, 0.2±0.1, 0.4 ± 0.1 h, respectively, the tin values of 9-NCwere 1.9 ± 1.3, 1.0 ± 0.6 and 2.8 ± 1.5 h, respectively, and AUC0-1 were 8.9±7.2, 16+ 12 and 60±26 ng· h· ml^-1 , respeetively. The values of t1/2 and ke of 9- NC were independent of dose ( P 〉 0.05). The absolute oral bioavailability of 9-NC was less than 6%. CONCLUSION: After iv or ig administration of 9-NC, the time eourse of plasma eoneentmtion in dogs eomplies with a two-eompartment model. The kinetie process of 9-NC in dogs is linear in the range of the experimental dosage. 9- NC is absorbed rapidly after ig administration and the oral bioavailability is poor.
出处 《中国临床药理学与治疗学》 CAS CSCD 2005年第11期1219-1224,共6页 Chinese Journal of Clinical Pharmacology and Therapeutics
关键词 9-硝基喜树碱 药代动力学 高效液相色谱 液相-质谱联用 9-nitro-camptothecin pharmacokinet-ics dogs HPLC HPLC-MS
  • 相关文献

参考文献5

二级参考文献17

  • 1[1]Pantazis P, Earuj JA, Kozielski AJ, et al. Regression of human breast carcinoma tumors in immunodeficient mice treated with 9-nitrocamptothecin: differential response of nontumorigenic and tumorigenic human breast cells in vitro [J]. Cancer Res, 1993,53(7) :1577 - 1582.
  • 2[2]Sands H, Mishra A, Stoeckler JD, et al. Preclinical activity of an iv formulation of rubitecan in IDD-PTM against human solid tumor xenografts [ J ]. Anticancer Drugs, 2002,13 (9): 965 - 975.
  • 3[3]Zhong DF, Li K, Xu JH, et al. Pharmacokinetics of 9-nitro-20 (S) -camptothecin in rats [ J ]. Acta Pharmacol Sin, 2003,24 (3) :256 - 262.
  • 4[4]Creemers GJ, Gervits CJH, Eckhardt J. Phase Ⅰ and pharmacologic study of oral topotecan administered twice daily for 21 days to adult patients with solid tumors [J].J Clin Oncol, 1997,15(3) :1087 - 1090.
  • 5[5]Chu XY, Suzuki H, Ueda K, et al. Active efflux of CPT-11 and its metabolites in human KB-derived cell lines[J]. J Pharmacol Exp Ther , 1999,288(2) :735 -741.
  • 6[6]Artursson P, Palm K, Luthman K. Caco-2 monolayers in experimental and theoretical predictions of drug transport[J]. Adv DrugDeliv Rev, 2001,46(1 -3):27 -43.
  • 7[7]Hu M, Chen J, Zhu Y, et al. Mechanism and kinetics of transcellular transport of a new lactam antibiotic loracarbef across an human intestinal epithelial model system (Caco-2) [J]. PharmRes, 1994,11(12):1405-1413.
  • 8[8]Monkkonen H, Tormalehto S, Asunmaa K, et al.Cellular uptake and metabolism of clodronate and its derivatives in Caco-2 cells: a possible correlation with bisphosphonate-induced gastrointestinal side-effects [J].Eur J Pharm Sci, 2003,19( 1 ) :23 -29.
  • 9[9]Warner DL, Burke TG. Simple and versatile highperformance liquid chromatographic method for the simultaneous quantity of the lactone and carboxylate forms of camptothecin anticancer drugs [ J ]. J Chromatogr B Biomed Appl, 1997,691 ( 1 ): 161 - 171.
  • 10[10]Chen JY, Hu M, Zhu YP, et al. The study of kinetic model for the drug efflux from a human intestinal epithelial membrane model system [ J ]. Acta Acad Med Shanghai (上海医科大学学报), 1996,23(4):247 -251.

共引文献37

同被引文献27

引证文献4

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部